Longitudinal course of clinical lung clearance index in children with cystic fibrosis
- PMID: 33361098
- DOI: 10.1183/13993003.02686-2020
Longitudinal course of clinical lung clearance index in children with cystic fibrosis
Abstract
Background: Although the lung clearance index (LCI) is a sensitive marker of small airway disease in individuals with cystic fibrosis (CF), less is known about longitudinal changes in LCI during routine clinical surveillance. Here, our objectives were to describe the longitudinal course of LCI in children with CF during routine clinical surveillance and assess influencing factors.
Methods: Children with CF aged 3-18 years performed LCI measurements every 3 months as part of routine clinical care between 2011 and 2018. We recorded clinical data at every visit. We used a multilevel mixed effect model to determine changes in LCI over time and identify clinical factors that influence LCI course.
Results: We collected LCI measurements from 1204 visits (3603 trials) in 78 participants, of which 907 visits had acceptable LCI data. The average unadjusted increase in LCI for the entire population was 0.29 (95% CI 0.20-0.38) LCI units·year-1. The increase in LCI was more pronounced in adolescence (0.41 (95% CI 0.27-0.54) LCI units·year-1). Colonisation with either Pseudomonas aeruginosa or Aspergillus fumigatus, pulmonary exacerbations, CF-related diabetes and bronchopulmonary aspergillosis were associated with a higher increase in LCI over time. Adjusting for clinical risk factors reduced the increase in LCI over time to 0.24 (95% CI 0.16-0.33) LCI units·year-1.
Conclusions: LCI measured during routine clinical surveillance is associated with underlying disease progression in children with CF. An increased change in LCI over time should prompt further diagnostic intervention.
Copyright ©ERS 2021. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: B.S. Frauchiger has nothing to disclose. Conflict of interest: S. Binggeli has nothing to disclose. Conflict of interest: S. Yammine reports grants from Swiss National Science Foundation, outside the submitted work. Conflict of interest: B. Spycher reports grants from Swiss National Science Foundation and Swiss Cancer League, outside the submitted work. Conflict of interest: L. Krüger has nothing to disclose. Conflict of interest: K.A. Ramsey reports grants from Swiss National Science Foundation, outside the submitted work. Conflict of interest: P. Latzin reports grants from Vertex, during the conduct of the study; personal fees from Vertex, Novartis, Roche, Polyphor, Vifor, Gilead, Schwabe, Zambon and Santhera, grants from Vertex, outside the submitted work.
Comment in
-
Sensitive markers to detect progression of lung disease in children with cystic fibrosis.Eur Respir J. 2021 Jul 8;58(1):2100236. doi: 10.1183/13993003.00236-2021. Print 2021 Jul. Eur Respir J. 2021. PMID: 34244301 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical